JAB-23E73 / Jacobio Pharma - LARVOL DELTA

Jacobio Pharma Announces 2024 Annual Results (PRNewswire) - "JAB-23E73: The dose escalation phase is expected to be completed in the second half of 2025."

Trial status • Oncology • Solid Tumor

Jacobio Pharma Completes First Patient Dosage of Pan-KRAS Inhibitor (Jacobio Press Release) - "Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, today announced that it has completed the first patient dosage of Pan-KRAS inhibitor (JAB-23E73) in the Phase I/IIa clinical study in China."

Trial status • Oncology

Jacobio Pharma Received Pan-KRAS Inhibitor IND Approval from China CDE (Jacobio Press Release) - "Jacobio Pharma...announced that it received IND (investigative new drug) approval from the China CDE....JAB-23E73 can inhibit both the active ('ON'）and inactive ('OFF') states of KRAS and with no obvious inhibition to HRAS or NRAS."

New trial • Oncology • Solid Tumor

Jacobio Pharma Received Pan-KRAS Inhibitor IND Approval from FDA (Jacobio Press Release) - "Jacobio Pharma...announced that it received IND (investigative new drug) approval from the U.S. FDA of Pan-KRAS inhibitor JAB-23E73, and Jacobio plans to initiate phase I/IIa clinical trial in advanced solid tumor patients. The China IND has been submitted, and China clinical trial will be initiated after China IND approval...JAB-23E73 can inhibit both the active ('ON'）and inactive ('OFF') states of KRAS and with no obvious inhibition to HRAS or NRAS. As an oral KRAS inhibitor, JAB-23E73's preclinical data showed good pharmacokinetic profile."

IND • New P1/2 trial • Solid Tumor

Jacobio Pharma Announces 2023 Annual Results (PRNewswire) - "KRASmulti inhibitor JAB-23E73: The IND application is expected to be submitted in Q2 2024; Clinical candidate for HER2-STING iADC JAB-BX400 is expected to be nominated in the second half of 2024."

Clinical • IND • Oncology • Solid Tumor